CITE-seq analysis showed a decrease in CD69 expression (prognostic factor) correlated to clinical progression in CLL at three months post-treatment, and subsequent increase at month 27 correlating with disease progression14. This evidence concerns the gene CD69 and B-cell chronic lymphocytic leukemia.